In a recent study, investigators examined the effects of both the short- and long-term use of selective serotonin-reuptake inhibitors (SSRIs) on the development and loss of bone. The study results describe the mechanisms by which SSRIs, specifically fluoxetine, affect osteoclasts short term to increase bone mass, but also how the treatment may cause bone loss at six weeks in mice…
Th17 May Contribute to Bone Destruction by Modifying Osteoclasts
New research describes the role of RANKL-expressing Th17 cells in inflammatory bone destruction. (posted June 3, 2013)